This is a preview.
Sign in or create a free account to view the full dataset, chart and data table.
Sign in or create a free account to view this dataset's chart and data table.
Key Takeaway
- Cardiovascular system medicines recorded a CAGR of 7% between FY 2019–20 and FY 2024–25, indicating strong sales growth. The category includes cardiac reactants and clotting agents. Its growth rate places it among the faster-growing broad medicine categories in the dataset.
About This Dataset
Annual sales data for animal health cardiovascular products, including cardiac reactants and clotting agents used in the management of cardiovascular conditions and related clinical requirements. The dataset tracks aggregated sales by financial year from 1 July to 30 June.
Methodology
Sign in or create a free account to view this dataset's methodology and sources.
You have subscriber access to this dataset
Available formats: Excel, CSV, PNG, PDF.
A downloadable report hasn't been published for this dataset yet.
View Subscription Plans
Request Demo
ENTERPRISE ACCESS
Transform Data Into Better Business Decisions
Join organizations that rely on statSCALAR for trusted market intelligence, industry statistics, commodity insights and enterprise research.
100+
Industries Included
150+
Countries
50K+
Data Points
24×7
Enterprise Access